share_log

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K：外國發行人報告
美股SEC公告 ·  07/18 08:01
Moomoo AI 已提取核心訊息
Alterity Therapeutics Limited, a development stage enterprise, has announced a new securities issue on July 18, 2024. The company, listed under the ASX issuer code ATH, plans to issue a total of 75,220,800 ordinary fully paid shares at an issue price of AUD 0.00540 per share. The purpose of the issue is to support further research and development activities and provide ongoing working capital. The issue will proceed without the need for security holder approval, utilizing the company's additional 10% placement capacity under listing rule 7.1A, chosen for its cost-effectiveness and timing benefits over other methods such as a pro rata issue or a security purchase plan. The newly issued securities will rank equally with existing securities and are not subject to any restrictions or voluntary escrow.
Alterity Therapeutics Limited, a development stage enterprise, has announced a new securities issue on July 18, 2024. The company, listed under the ASX issuer code ATH, plans to issue a total of 75,220,800 ordinary fully paid shares at an issue price of AUD 0.00540 per share. The purpose of the issue is to support further research and development activities and provide ongoing working capital. The issue will proceed without the need for security holder approval, utilizing the company's additional 10% placement capacity under listing rule 7.1A, chosen for its cost-effectiveness and timing benefits over other methods such as a pro rata issue or a security purchase plan. The newly issued securities will rank equally with existing securities and are not subject to any restrictions or voluntary escrow.
Alterity Therapeutics有限公司（一家開發階段企業）於2024年7月18日宣佈發行新證券。該公司在ASX發行人代碼ATH下進行上市，計劃發行總計75,220,800份普通全額支付股票，每股發行價格爲AUD 0.00540。本次發行的目的是支持進一步的研發活動並提供持續的營運資金，並且不需要股東批准，利用公司根據7.1A上市規則的額外10%配售能力進行，其他方法，如按比例配售或安排安置計劃的成本效益和時機優勢選擇。新發行的證券與現有證券享有同等地位，不受任何限制或自願託管。
Alterity Therapeutics有限公司（一家開發階段企業）於2024年7月18日宣佈發行新證券。該公司在ASX發行人代碼ATH下進行上市，計劃發行總計75,220,800份普通全額支付股票，每股發行價格爲AUD 0.00540。本次發行的目的是支持進一步的研發活動並提供持續的營運資金，並且不需要股東批准，利用公司根據7.1A上市規則的額外10%配售能力進行，其他方法，如按比例配售或安排安置計劃的成本效益和時機優勢選擇。新發行的證券與現有證券享有同等地位，不受任何限制或自願託管。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間